ABEO Stock: Abeona Therapeutics Inc. Stock Price, Analysis & Insights
Get live abeo stock price $4.87, comprehensive Abeona Therapeutics Inc. stock analysis, charts, news, and expert forecast. Real-time abeo stock data and investment insights.
Loading chart...
Company Overview
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Company Information
- CEO
- Vishwas Seshadri
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 136
Contact Information
- Address
- 1330 Avenue of the Americas
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 4.0)
Business Model & Strategy
Abeona Therapeutics Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Vishwas Seshadri, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Abeona Therapeutics Inc. competes in the Biotechnology within the broader Healthcare. With 243.5 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Abeona Therapeutics Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Abeona Therapeutics Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Abeona Therapeutics Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Abeona Therapeutics Inc.
- ⚠Investors should consider how Abeona Therapeutics Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
243.50M
P/E Ratio
4.02
Beta
1.11
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 243.50M market capitalization
- Trading Volume: 646.37K shares traded today
- Price Range: 52-week range of $3.93 - $7.54
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Abeona Therapeutics Inc.
Abeona Therapeutics Inc. (ABEO) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 243.50M, the company represents a significant player in its market. The stock is currently trading at $4.87 with a positivedaily change of 0.00%.
The company's 136 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 4.02, beta of 1.11, and 52-week price range from $3.93 to $7.54when evaluating investment opportunities.
Why Invest in Abeona Therapeutics Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Vishwas Seshadri
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.